vs
BIOMERICA INC（BMRA）与IMMUCELL CORP（ICCC）财务数据对比。点击上方公司名可切换其他公司
IMMUCELL CORP的季度营收约是BIOMERICA INC的4.6倍（$5.5M vs $1.2M）。IMMUCELL CORP净利率更高（-2.5% vs -109.1%，领先106.6%）。IMMUCELL CORP同比增速更快（-8.4% vs -26.0%）。过去两年BIOMERICA INC的营收复合增速更高（9.1% vs 3.9%）
Biomerica Inc.是一家全球性医疗技术企业，研发、生产及销售诊断检测试剂盒与相关医疗产品，产品线覆盖胃肠疾病、传染病、食物不耐受检测及即时检测解决方案，服务全球多地的临床实验室、医疗机构及零售医疗客户。
ImmuCell Corp是一家总部位于美国的动物健康生物技术企业，主要研发、生产和销售以奶牛为主的家畜相关保健与治疗产品，核心产品包括乳腺炎等常见牛类疾病的防治方案，主要服务北美地区的畜牧养殖户和兽医机构。
BMRA vs ICCC — 直观对比
营收规模更大
ICCC
是对方的4.6倍
$1.2M
营收增速更快
ICCC
高出17.6%
-26.0%
净利率更高
ICCC
高出106.6%
-109.1%
两年增速更快
BMRA
近两年复合增速
3.9%
损益表 — Q2 2026 vs Q3 2025
| 指标 | | |
|---|---|---|
| 营收 | $1.2M | $5.5M |
| 净利润 | $-1.3M | $-139.7K |
| 毛利率 | 4.2% | 42.9% |
| 营业利润率 | -113.5% | 0.4% |
| 净利率 | -109.1% | -2.5% |
| 营收同比 | -26.0% | -8.4% |
| 净利润同比 | -38.9% | 80.1% |
| 每股收益（稀释后） | $-0.45 | $-0.02 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BMRAICCC
| Q4 25 | $1.2M | — | ||
| Q3 25 | $1.4M | $5.5M | ||
| Q2 25 | $749.0K | $6.4M | ||
| Q1 25 | $1.1M | $8.1M | ||
| Q4 24 | $1.6M | $7.8M | ||
| Q3 24 | $1.8M | $6.0M | ||
| Q2 24 | $1.1M | $5.5M | ||
| Q1 24 | $1.0M | $7.3M |
净利润BMRAICCC
| Q4 25 | $-1.3M | — | ||
| Q3 25 | $2.0K | $-139.7K | ||
| Q2 25 | $-1.5M | $501.9K | ||
| Q1 25 | $-1.2M | $1.4M | ||
| Q4 24 | $-950.0K | — | ||
| Q3 24 | $-1.3M | $-701.7K | ||
| Q2 24 | $-1.4M | $-1.5M | ||
| Q1 24 | $-1.9M | $-437.9K |
毛利率BMRAICCC
| Q4 25 | 4.2% | — | ||
| Q3 25 | 30.7% | 42.9% | ||
| Q2 25 | -33.0% | 43.7% | ||
| Q1 25 | 1.7% | 41.6% | ||
| Q4 24 | 26.7% | 36.5% | ||
| Q3 24 | 16.0% | 26.3% | ||
| Q2 24 | 2.1% | 22.5% | ||
| Q1 24 | -14.7% | 31.6% |
营业利润率BMRAICCC
| Q4 25 | -113.5% | — | ||
| Q3 25 | -81.0% | 0.4% | ||
| Q2 25 | -209.1% | 8.8% | ||
| Q1 25 | -108.1% | 13.9% | ||
| Q4 24 | -60.7% | 8.0% | ||
| Q3 24 | -75.7% | -9.6% | ||
| Q2 24 | -136.6% | -25.3% | ||
| Q1 24 | -196.7% | -4.1% |
净利率BMRAICCC
| Q4 25 | -109.1% | — | ||
| Q3 25 | 0.1% | -2.5% | ||
| Q2 25 | -206.1% | 7.8% | ||
| Q1 25 | -103.9% | 17.9% | ||
| Q4 24 | -58.1% | — | ||
| Q3 24 | -72.8% | -11.7% | ||
| Q2 24 | -127.1% | -28.0% | ||
| Q1 24 | -188.6% | -6.0% |
每股收益（稀释后）BMRAICCC
| Q4 25 | $-0.45 | — | ||
| Q3 25 | $0.00 | $-0.02 | ||
| Q2 25 | $-0.99 | $0.06 | ||
| Q1 25 | $-0.48 | $0.16 | ||
| Q4 24 | $-0.06 | $0.09 | ||
| Q3 24 | $-0.63 | $-0.09 | ||
| Q2 24 | $-2.57 | $-0.20 | ||
| Q1 24 | $-0.11 | $-0.06 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $2.5M | $3.9M |
| 总债务越低越好 | — | $9.5M |
| 股东权益账面价值 | $4.4M | $29.8M |
| 总资产 | $6.0M | $45.7M |
| 负债/权益比越低杠杆越低 | — | 0.32× |
8季度趋势，按日历期对齐
现金及短期投资BMRAICCC
| Q4 25 | $2.5M | — | ||
| Q3 25 | $3.1M | $3.9M | ||
| Q2 25 | $3.1M | — | ||
| Q1 25 | $3.1M | — | ||
| Q4 24 | $2.4M | $3.8M | ||
| Q3 24 | $2.8M | — | ||
| Q2 24 | $4.2M | $1.3M | ||
| Q1 24 | $5.3M | $960.3K |
总债务BMRAICCC
| Q4 25 | — | — | ||
| Q3 25 | — | $9.5M | ||
| Q2 25 | — | — | ||
| Q1 25 | — | $8.7M | ||
| Q4 24 | — | $9.0M | ||
| Q3 24 | — | $9.4M | ||
| Q2 24 | — | $9.8M | ||
| Q1 24 | — | $10.2M |
股东权益BMRAICCC
| Q4 25 | $4.4M | — | ||
| Q3 25 | $5.2M | $29.8M | ||
| Q2 25 | $4.1M | $29.9M | ||
| Q1 25 | $5.5M | $29.0M | ||
| Q4 24 | $5.1M | $27.5M | ||
| Q3 24 | $5.3M | $26.4M | ||
| Q2 24 | $6.6M | $23.5M | ||
| Q1 24 | $7.8M | $24.6M |
总资产BMRAICCC
| Q4 25 | $6.0M | — | ||
| Q3 25 | $6.9M | $45.7M | ||
| Q2 25 | $5.9M | $46.7M | ||
| Q1 25 | $7.4M | $45.6M | ||
| Q4 24 | $7.3M | $45.1M | ||
| Q3 24 | $7.9M | $44.4M | ||
| Q2 24 | $9.3M | $41.9M | ||
| Q1 24 | $10.3M | $43.1M |
负债/权益比BMRAICCC
| Q4 25 | — | — | ||
| Q3 25 | — | 0.32× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 0.30× | ||
| Q4 24 | — | 0.33× | ||
| Q3 24 | — | 0.36× | ||
| Q2 24 | — | 0.42× | ||
| Q1 24 | — | 0.41× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-991.0K | $-1.2M |
| 自由现金流经营现金流 - 资本支出 | — | $-1.8M |
| 自由现金流率自由现金流/营收 | — | -32.3% |
| 资本支出强度资本支出/营收 | — | 10.8% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $715.4K |
8季度趋势，按日历期对齐
经营现金流BMRAICCC
| Q4 25 | $-991.0K | — | ||
| Q3 25 | $-268.0K | $-1.2M | ||
| Q2 25 | $-661.0K | $1.6M | ||
| Q1 25 | $-1.0M | $1.6M | ||
| Q4 24 | $-791.0K | $-3.1K | ||
| Q3 24 | $-1.3M | $-639.3K | ||
| Q2 24 | $-1.0M | $581.8K | ||
| Q1 24 | $-1.8M | $418.5K |
自由现金流BMRAICCC
| Q4 25 | — | — | ||
| Q3 25 | — | $-1.8M | ||
| Q2 25 | — | $1.4M | ||
| Q1 25 | — | $1.2M | ||
| Q4 24 | — | $-199.3K | ||
| Q3 24 | — | $-727.7K | ||
| Q2 24 | $-1.1M | $471.0K | ||
| Q1 24 | — | $348.1K |
自由现金流率BMRAICCC
| Q4 25 | — | — | ||
| Q3 25 | — | -32.3% | ||
| Q2 25 | — | 22.4% | ||
| Q1 25 | — | 15.4% | ||
| Q4 24 | — | -2.6% | ||
| Q3 24 | — | -12.1% | ||
| Q2 24 | -95.5% | 8.6% | ||
| Q1 24 | — | 4.8% |
资本支出强度BMRAICCC
| Q4 25 | — | — | ||
| Q3 25 | — | 10.8% | ||
| Q2 25 | — | 2.4% | ||
| Q1 25 | — | 4.1% | ||
| Q4 24 | — | 2.5% | ||
| Q3 24 | — | 1.5% | ||
| Q2 24 | 2.1% | 2.0% | ||
| Q1 24 | 0.0% | 1.0% |
现金转化率BMRAICCC
| Q4 25 | — | — | ||
| Q3 25 | -134.00× | — | ||
| Q2 25 | — | 3.19× | ||
| Q1 25 | — | 1.09× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
